ArticleJournal of neurology2026
Risk of ischemic stroke following amaurosis fugax versus transient ischemic attack.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesAmaurosis fugax is conventionally classified as a transient ischemic attack (TIA) subtype, yet the landmark trials guiding TIA management did not specifically enroll patients with amaurosis fugax. Clinicians frequently extrapolate TIA trial data to amaurosis fugax, potentially exposing patients to suboptimal diagnostic and treatment plans. We compared the risk of subsequent ischemic stroke after amaurosis fugax versus TIA.
methodsUsing the Nationwide Readmissions Database (2016-2022), we identified non-elective hospitalizations with a primary diagnosis of TIA or amaurosis fugax. Patients with amaurosis fugax were matched 1:2 to TIA patients using propensity-score matching on 25 covariates. Primary and secondary outcomes were any ischemic stroke and disabling ischemic stroke readmission, respectively, over 300 days. Additional 300-day outcomes were any non-elective readmission, major hemorrhage, intracranial hemorrhage, and death.
resultsA total of 131,791 patients were identified, and after matching 4350 amaurosis fugax and 8,698 TIA patients remained. Patients with amaurosis fugax had significantly lower cumulative stroke probabilities (300-day: 1.5% vs 3.3%; HR 0.49 [95% CI 0.28-0.84], p = 0.01). Disabling stroke was similarly lower (HR 0.47 [95% CI 0.22-0.99], p = 0.048). Non-elective readmission was also lower (HR 0.84 [95% CI 0.73-0.98], p = 0.023), whereas major hemorrhage, intracranial hemorrhage, and death did not differ between groups. DISCUSSION: Amaurosis fugax carries approximately half the subsequent stroke risk of TIA, without a corresponding excess of hemorrhage or death, suggesting these conditions have distinct natural histories, and patients with amaurosis fugax would likely benefit from distinct diagnostic evaluation and individualized risk-benefit assessments beyond simple application of TIA-derived diagnostic and treatment protocols.
Indexed as
Identifiers
42640503What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.